Who
Jason R. Kelly
Director and Officer
Company insider
Files Form 4 as: CEO & Founder, Ginkgo Bioworks Holdings.
In numbers
- Trades disclosed
- 202
- Buys
- 0
- Sells
- 168
- Bought
- $0
- Sold
- $46.6M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 16 Sep 2021
- Last trade
- 28 Jul 2026
- Last filed
- 30 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Jul 2026filed 30 Jul 2026 | DNA Ginkgo Bioworks Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,258 | filing |
| 28 Jul 2026filed 30 Jul 2026 | DNA Ginkgo Bioworks Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —309,467 | filing |
| 28 Jul 2026filed 30 Jul 2026 | DNA Ginkgo Bioworks Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,258 | filing |
| 28 Jul 2026filed 30 Jul 2026 | DNA Ginkgo Bioworks Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —309,467 | filing |
| 9 Apr 2026filed 10 Apr 2026 | DNA Ginkgo Bioworks HoldingsBiotechnology | SEC FORM 4 Sold | $702K109,767 at $6.40 | filing |
| 9 Apr 2026filed 10 Apr 2026 | DNA Ginkgo Bioworks HoldingsBiotechnology | SEC FORM 4 Sold | $703K109,767 at $6.40 | filing |
| 8 Apr 2026filed 10 Apr 2026 | DNA Ginkgo Bioworks HoldingsBiotechnology | SEC FORM 4 Code M | —212,949 | filing |
| 8 Apr 2026filed 10 Apr 2026 | DNA Ginkgo Bioworks HoldingsBiotechnology | SEC FORM 4 Sold | $672K97,015 at $6.93 | filing |
| 8 Apr 2026filed 10 Apr 2026 | DNA Ginkgo Bioworks Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —212,949 | filing |
| 8 Apr 2026filed 10 Apr 2026 | DNA Ginkgo Bioworks Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —212,949 | filing |
| 8 Apr 2026filed 10 Apr 2026 | DNA Ginkgo Bioworks HoldingsBiotechnology | SEC FORM 4 Code M | —212,949 | filing |
| 8 Apr 2026filed 10 Apr 2026 | DNA Ginkgo Bioworks HoldingsBiotechnology | SEC FORM 4 Sold | $672K97,015 at $6.93 | filing |
| 7 Apr 2026filed 10 Apr 2026 | DNA Ginkgo Bioworks HoldingsBiotechnology | SEC FORM 4 Code M | —212,949 | filing |
| 7 Apr 2026filed 10 Apr 2026 | DNA Ginkgo Bioworks Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —212,949 | filing |
| 7 Apr 2026filed 10 Apr 2026 | DNA Ginkgo Bioworks Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —212,949 | filing |
| 7 Apr 2026filed 10 Apr 2026 | DNA Ginkgo Bioworks HoldingsBiotechnology | SEC FORM 4 Code M | —212,949 | filing |
| 25 Apr 2024filed 29 Apr 2024 | DNA Ginkgo Bioworks Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000,000 at $0.00 | filing |
| 4 Jan 2024filed 5 Jan 2024 | DNA Ginkgo Bioworks HoldingsBiotechnology | SEC FORM 4 Sold | $156K100,000 at $1.56 | filing |
| 3 Jan 2024filed 5 Jan 2024 | DNA Ginkgo Bioworks HoldingsBiotechnology | SEC FORM 4 Sold | $154K100,000 at $1.54 | filing |
| 21 Dec 2023filed 22 Dec 2023 | DNA Ginkgo Bioworks HoldingsBiotechnology | SEC FORM 4 Sold | $174K100,000 at $1.74 | filing |
News
No headline names them, or the companies they trade most, lately.